Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and feasibility without systematic review methodology or new clinical data.
PubMed 34069909 · doi:10.3390/ijms22105302
What was done
This narrative review summarizes the biological properties, paracrine mechanisms, and therapeutic potential of allogeneic human placenta-derived stromal cells (hPSCs/f-hPSCs) compared to bone marrow and adipose-derived mesenchymal stromal cells, discussing preclinical and clinical feasibility studies.
What was found
No quantitative data or statistical comparisons are reported in the abstract. The authors report that neonate-derived placenta stromal cells undergo extended expansion with low risk of senescence, maintain low expression of HLA class I and II to limit immune rejection in allogeneic settings, and act primarily via paracrine secretion of pro-regenerative and anti-inflammatory factors.
Why it matters
Human term placenta provides an abundant, non-invasively obtained source of allogeneic stromal cells, circumventing the harvesting limitations and yield constraints of autologous bone marrow.
Limits
This is an unsystematic narrative review providing qualitative summaries rather than pooled clinical outcomes. The abstract provides no sample sizes, specific disease outcomes, adverse event rates, or quantitative metrics.
Cited by
- context Placental stem cells have not been thymized and do not provoke an immune reaction when administered to any recipient.